Compare TKNO & KRAQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TKNO | KRAQ |
|---|---|---|
| Founded | 1996 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.7M | 432.1M |
| IPO Year | 2021 | 2026 |
| Metric | TKNO | KRAQ |
|---|---|---|
| Price | $9.00 | $10.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 254.4K | 35.6K |
| Earning Date | 11-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $13.53 | N/A |
| Revenue Next Year | $14.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $9.78 |
| 52 Week High | $9.48 | $10.44 |
| Indicator | TKNO | KRAQ |
|---|---|---|
| Relative Strength Index (RSI) | 71.35 | 50.87 |
| Support Level | $4.87 | $9.92 |
| Resistance Level | $9.48 | $10.04 |
| Average True Range (ATR) | 0.53 | 0.01 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 87.63 | 25.58 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Krakacquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.